BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36401024)

  • 1. Cardiac and Skeletal Muscle Pathology in the D2/mdx Mouse Model and Caveats Associated with the Quantification of Utrophin.
    Kennedy TL; Dugdale HF
    Methods Mol Biol; 2023; 2587():55-66. PubMed ID: 36401024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy.
    Hammers DW; Hart CC; Matheny MK; Wright LA; Armellini M; Barton ER; Sweeney HL
    Sci Rep; 2020 Aug; 10(1):14070. PubMed ID: 32826942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
    Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A
    EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy.
    Ito M; Ehara Y; Li J; Inada K; Ohno K
    Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
    Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
    Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation compound for the modulation of utrophin in the therapy of DMD.
    Guiraud S; Squire SE; Edwards B; Chen H; Burns DT; Shah N; Babbs A; Davies SG; Wynne GM; Russell AJ; Elsey D; Wilson FX; Tinsley JM; Davies KE
    Hum Mol Genet; 2015 Aug; 24(15):4212-24. PubMed ID: 25935002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural disease history of the D2
    van Putten M; Putker K; Overzier M; Adamzek WA; Pasteuning-Vuhman S; Plomp JJ; Aartsma-Rus A
    FASEB J; 2019 Jul; 33(7):8110-8124. PubMed ID: 30933664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
    Janssen PM; Murray JD; Schill KE; Rastogi N; Schultz EJ; Tran T; Raman SV; Rafael-Fortney JA
    PLoS One; 2014; 9(2):e88360. PubMed ID: 24551095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice.
    van Putten M; Hulsker M; Young C; Nadarajah VD; Heemskerk H; van der Weerd L; 't Hoen PA; van Ommen GJ; Aartsma-Rus AM
    FASEB J; 2013 Jun; 27(6):2484-95. PubMed ID: 23460734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of gene expression differences between utrophin/dystrophin-deficient vs mdx skeletal muscles reveals a specific upregulation of slow muscle genes in limb muscles.
    Baker PE; Kearney JA; Gong B; Merriam AP; Kuhn DE; Porter JD; Rafael-Fortney JA
    Neurogenetics; 2006 May; 7(2):81-91. PubMed ID: 16525850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/
    Kennedy TL; Guiraud S; Edwards B; Squire S; Moir L; Babbs A; Odom G; Golebiowski D; Schneider J; Chamberlain JS; Davies KE
    Mol Ther Methods Clin Dev; 2018 Dec; 11():92-105. PubMed ID: 30417024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing muscle contractility through low-frequency stimulation alters tibial bone geometry and reduces bone strength in
    Chan AS; Hardee JP; Blank M; Cho EH; McGregor NE; Sims NA; Lynch GS
    J Appl Physiol (1985); 2023 Jul; 135(1):77-87. PubMed ID: 37262103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.
    Rafael JA; Tinsley JM; Potter AC; Deconinck AE; Davies KE
    Nat Genet; 1998 May; 19(1):79-82. PubMed ID: 9590295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sparing of extraocular muscle in dystrophinopathy is lost in mice lacking utrophin and dystrophin.
    Porter JD; Rafael JA; Ragusa RJ; Brueckner JK; Trickett JI; Davies KE
    J Cell Sci; 1998 Jul; 111 ( Pt 13)():1801-11. PubMed ID: 9625743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.